Caulerpa racemosa

Caulerpa racemosa has been studied in 1 paper since 2022: 1 trial in people. The newest paper, Jul 14, 2022: “Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels”.

Intervention

1 paper studies it6 findingsUpdated

See all 1 papers on caulerpa racemosa

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“After 4 weeks of intervention, there was a significant decrease (p < 0.05) in BG, TC, LDL, TG, waist circumference, WHR (p = 0.000), and body weight (p = 0.026).”
Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α LevelsFrontiers in nutrition2022doi:10.3389/fnut.2022.939073

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funder: University of Brawijaya
  • Human trial1

Studies in people

1 study gave caulerpa racemosa to people and measured what changed.

What changedDesignPeopleSource

down: Decreases body weight

up: Increases high-density lipoprotein cholesterol

Trial4 weeks70 peopleOnly men29.98 ± 3.26 yearsObese men without other diagnosed diseasesFrontiers in nutrition, Jul 14, 2022

What did studies of caulerpa racemosa find?

3

Studies of caulerpa racemosa measured 3 outcomes: PPARGC1A, high-density lipoprotein cholesterol and body weight.

PPARGC1A

upin humans1

1 study
  1. Caulerpa racemosa increases PPARGC1A in humans (compared with placebo).

    “There was also a significant increase (p = 0.000) in PGC-1α and HDL, respectively, in the sea grape extract group when compared with the placebo group.”

    Human trialcompared with placebo4 weeksn = 69

    Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels

    Frontiers in nutrition

  2. Caulerpa racemosa increases PPARGC1A in humans (compared with Group A) (p = 0.000).

    “PGC-1α and high-density lipoprotein (HDL) increased significantly (p = 0.000), in Group B when compared with Group A.”

    Human trialcompared with Group A4-week

    Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels

    Frontiers in nutrition

More on PPARGC1A

High-density lipoprotein cholesterol

upin humans1

1 study
  1. Caulerpa racemosa increases high-density lipoprotein cholesterol in humans (compared with placebo).

    “There was also a significant increase (p = 0.000) in PGC-1α and HDL, respectively, in the sea grape extract group when compared with the placebo group.”

    Human trialcompared with placebo4 weeksn = 69

    Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels

    Frontiers in nutrition

  2. Caulerpa racemosa increases high-density lipoprotein cholesterol in humans (compared with Group A) (p = 0.000).

    “PGC-1α and high-density lipoprotein (HDL) increased significantly (p = 0.000), in Group B when compared with Group A.”

    Human trialcompared with Group A4-week

    Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels

    Frontiers in nutrition

More on High-density lipoprotein cholesterol

Body weight

downin humans1

1 study
  1. Caulerpa racemosa decreases body weight in humans (compared with placebo).

    “After 4 weeks of intervention, there was a significant decrease (p < 0.05) in BG, TC, LDL, TG, waist circumference, WHR (p = 0.000), and body weight (p = 0.026).”

    Human trialcompared with placebo4 weeksn = 69

    Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels

    Frontiers in nutrition

  2. Caulerpa racemosa decreases body weight in humans (compared with Group A) (p < 0.05).

    “There was a significant decrease in blood glucose, total cholesterol, low-density lipoprotein (LDL), triglycerides (TG), waist circumference, waist-hip ratio, and body weight (p < 0.05)”

    Human trialcompared with Group A4-week

    Metabolomic Assay, Computational Screening, and Pharmacological Evaluation of Caulerpa racemosa as an Anti-obesity With Anti-aging by Altering Lipid Profile and Peroxisome Proliferator-Activated Receptor-γ Coactivator 1-α Levels

    Frontiers in nutrition

Latest